Travel Vaccines Market Share, Size and Growth Analysis By 2029

The travel vaccines market is anticipated to grow significantly, reaching an estimated US$ 5,914.22 million by 2028, up from US$ 3,078.94 million in 2021. This growth represents a compound annual growth rate (CAGR) of 9.8% from 2021 to 2028.

This report outlines the prevailing trends in the travel vaccines market and identifies key factors contributing to its expansion. The growth of the travel vaccines market is primarily driven by the surge in travel and tourism, heightened awareness regarding the prevention of transnational infections, and the increasing incidence of infectious diseases. However, the high costs associated with travel vaccines may pose challenges to market growth in the near future.

In recent decades, the travel and tourism sector has experienced remarkable growth, fueled by rising disposable incomes, improved travel routes, and a variety of transportation options. Tourists are increasingly eager to explore diverse cultures, traditions, and lifestyles. A recent survey conducted by The Millennial Travel Study by Skyscanner revealed that over 1,000 millennials (aged 18-35) were asked about their travel preferences, including destinations and modes of travel. The findings indicated that 80% of respondents favored international travel over domestic trips, with European destinations being particularly popular among travelers of all ages, followed by the United States and New Zealand.

Data from Our World in Data, sourced from the World Tourism Organization, highlighted a significant increase in tourism across various regions in 2019. For instance, the European Union recorded approximately 966.44 million arrivals, North America saw around 200 million, and the Middle East & North Africa welcomed about 128 million visitors. France alone accounted for 212 million arrivals, while Spain attracted 126.17 million. The total number of international arrivals reached 2.403 billion in 2019, with the European Union leading with 966.44 million arrivals, followed by East Asia & Pacific with 487.08 million. The estimated expenditure for international tourism was around US$ 1.439 billion. Although the COVID-19 pandemic severely disrupted this trend, the rollout of COVID-19 vaccinations and the implementation of safety regulations are expected to facilitate the recovery of tourism and travel.

The pandemic underscored the importance of immunizations for travelers to prevent the spread of infections. Different countries have established their own policies to safeguard travelers from infectious diseases. For example, in the UK, the National Health Service (NHS) conducts routine vaccination drives. Travelers leaving the UK are advised to receive vaccinations against diseases such as hepatitis A, typhoid, measles, mumps, and yellow fever. Similarly, in Saudi Arabia, pilgrims traveling for Hajj and Umrah must provide proof of vaccination against meningitis and seasonal influenza. Many countries require travelers to present vaccination documentation on an International Certificate of Vaccination or Prophylaxis (ICVP). Vaccinations are recommended against various diseases as outlined by the US Department of Health & Human Services, including chickenpox, cholera, COVID-19, diphtheria, influenza, hepatitis A and B, and more, depending on the destination. The growing concern over the transmission of regional diseases across borders is driving the demand for travel vaccines.

The global travel vaccines market is categorized by product types, including hepatitis A, hepatitis B, meningococcal vaccines, DPT (diphtheria, pertussis, tetanus), yellow fever, typhoid, Japanese encephalitis, measles, mumps & rubella, rabies, polio, influenza, varicella & shingles, cholera, and others. In 2021, the hepatitis A segment held the largest market share, while the DPT segment is projected to experience the highest CAGR during the forecast period. The market is also segmented by application into domestic travel and outbound travel, with the outbound travel segment holding a larger share in 2021 and expected to grow at a higher CAGR from 2021 to 2028.

The COVID-19 pandemic has resulted in both a public health and economic crisis, significantly impacting travel since early 2020. Travel restrictions imposed by governments to curb the spread of the virus led to a sharp decline in both domestic and international travel, which in turn reduced the demand for travel vaccines and hindered market growth.

As restrictions have eased and travel has resumed, there has been a renewed focus on the vaccination status of travelers. While the primary focus has been on COVID-19 vaccinations, there has been a corresponding increase in demand for other travel vaccines, as travelers and regulatory bodies emphasize the importance of timely vaccinations to protect both travelers and the communities they visit. Consequently, the travel vaccines market is poised for significant growth, driven by the emphasis on vaccination against infectious diseases.

Organizations such as the US Centers for Disease Control and Prevention, various National Health Services, and the World Health Organization have developed travel advisories to promote safe travel, further contributing to market growth.

Companies in the travel vaccines market are pursuing various organic and inorganic growth strategies. Many focus on organic growth through product launches and approvals, while inorganic strategies include acquisitions, collaborations, and partnerships. These strategies have enabled market players to expand their operations, enhance their geographic presence, and strengthen their customer base.

Recent notable developments in the travel vaccines market include:

• December 2021: Emergent BioSolutions Inc. announced the initiation of a phase 1 study for its investigational universal influenza vaccine candidate, EBS-UFV-001, aimed at evaluating its safety and immunogenicity.


• June 2021: Merck & Co., Inc. and Sanofi launched the Vaxelis vaccine, a hexavalent combination vaccine for active immunization against DTP, polio, and hepatitis B.


• March 2021: Sanofi invested over US$ 750 million in a new vaccine manufacturing facility in Toronto, Canada, to increase the supply of its Fluzone High-Dose Quadrivalent influenza vaccine.

Key sources referenced in the preparation of this report include the National Center for Health Statistics, the Centers for Disease Control and Prevention (CDC), and the World Tourism Organization (WTO).